Document is current
Any future updates will be listed below
-
Authors
Seiffge, David J. https://orcid.org/0000-0003-3890-3849
Fandler-Höfler, Simon https://orcid.org/0000-0001-9043-0378
Du, Yang
Goeldlin, Martina B. https://orcid.org/0000-0001-5800-116X
Jolink, Wilmar M. T. https://orcid.org/0000-0001-9497-9050
Klijn, Catharina J. M. https://orcid.org/0000-0002-8495-4578
Werring, David J. https://orcid.org/0000-0003-2074-1861
- License Information
-
More Information
Article History
Accepted: 11 October 2024
First Online: 15 November 2024
Competing interests
: DJW reports speaking honoraria from Bayer; speaking and chairing honoraria from Alexion and NovoNordisk; and consultancy fees from Alnylam, Bayer and NovoNordisk. He is Co-Chief Investigator for the PROHIBIT-ICH trial. He has participated as a member of the LACI-2, TICH-2, TICH-3, RESTART, MACE-ICH and PLINTH Trial Steering Committees. The other authors declare no competing interests.
